Brief: Geneuro FY revenues up at 6.4 million euros

Geneuro SA

31/01/2017 17:32

Jan 31 (Reuters) - GeNeuro SA  GNRO.PA : 
    * Full year revenues displayed a strong growth to 6.4 million euros ($6.90 million) versus 
2.5 million euros for 2015 
    * Cash and cash equivalents of 34.5 million euros at 31 December 2016 
    * Cash used for operations and investing activities was 16.0 million euros 
    * GeNeuro's strategy for 2017 remains fully focused on developing GNbAC1 for multiple 
sclerosis (MS), with 6-month top line results from change-ms expected in early Q4 2017 
    * Company also is preparing a phase 2A trial to study GNbAC1 in type 1 diabetes patients, 
which will be initiated in H1 2017. 
    * In addition, an U.S. phase 2 trial in secondary progressive MS patients will start in H2 
2017 
 
Source text for Eikon:  ID:nBw18JF74a  
Further company coverage:  GNRO.PA  
 
($1 = 0.9277 euros) 
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))